ABBV · 10-Q · 2026Q3 · Full report

Operating Expense Trends

AbbVie Inc. · 2026-11-03 · Importance 54 · Surprise 40 · In source text

SG&A expense was $4.087 billion for the third quarter and $11.297 billion for the first nine months of 2026, versus $3.569 billion and $10.115 billion in the corresponding 2025 periods. SG&A as a percentage of revenue was flat year over year: revenue growth leverage was offset by Apogee acquisition and integration costs, including cash-settled employee incentive awards and litigation reserve charges. R&D expense increased to $2.567 billion in the quarter and $7.383 billion for nine months, from $2.319 billion and $6.517 billion, as AbbVie funded pipeline programs.

Key facts

• For the nine months ended September 30, 2026, AbbVie incurred $5.1 billion of intangible-asset amortization, $4.7 billion of charges for changes in fair value of contingent consideration liabilities, and $431 million of acquisition and integration expenses. source
• AbbVie’s pipeline included approximately 100 compounds, devices, or indications in development, approximately 60 of them in mid- and late-stage development. source
• SG&A expense as a percentage of net revenues was flat for the three and nine months ended September 30, 2026; revenue-growth leverage was offset by higher Apogee acquisition and integration costs, including cash-settled post-closing employee incentive awards and litigation reserve charges. source
• AbbVie expected multiple mid-stage programs to transition into late-stage programs in the next 12 months. source
• R&D expense as a percentage of net revenues was flat for the three and nine months ended September 30, 2026, while R&D expenses increased to support all stages of AbbVie’s pipeline. source

Impact estimates